Home About History
History
2012 2014 2018 2019 2020 2021 2022 2023
2012
2012
Company name changed to CASI
2012
2014
Licensed in 3 clinical/commercial assets EVOMELA® , MARQIBO® , ZEVALIN®
2018
Launched R&D Production Site
EVOMELA® NMPA Approval
2019
EVOMELA® commercially launch in China
Licensed in CID-103
Licensed in CNCT-19
2019
2020
Licensed in BI-1206
Licensed in Thiotepa
2021
Licensed in CB-5339
2022
Wuxi site obtained GSP distribution certificate
Over 10,000 patients treated with EVOMELA® in China
2022
2023
More BD deals and NDAs expected
2023